The information on this site is not intended or implied to be a substitute for professional medical advice, diagnosis or treatment. Content within the patient forum is user-generated and has not been reviewed by medical professionals. Other sections of the Melanoma Research Foundation website include information that has been reviewed by medical professionals as appropriate. All medical decisions should be made in consultation with your doctor or other qualified medical professional.

Spartalizumab /3 Arm Clinical Trial

This topic has 3 replies, 2 voices, and was last updated 6 years ago by Linda5.

Post

- May 9, 2019 at 2:05 pm
- Quote
Linda5
Participant
Well, it looks like my run with Taf/Mek has come to an end with two new lung nodules appearing and growing over the last three months. I have already tried pembro and ipi – the only real impact came with added radiation, but had progression after and went back to Taf /Mek for 17 months.

I’ve been offered a clinical trial which I believe is called the PLATforM trial…spartalizumab plus one of three other drugs – lag525, capmatinib, or canakinumab. I will find out more next week, but thought I’d see if anyone here knew anything or was participating?

Thank you in advance!
Linda

Viewing 0 reply threads

Replies

- - May 9, 2019 at 3:04 pm
  - Quote
  ed williams
  Participant
  Hi Linda, my understanding of PDR-001 now called Spartalizumab is it is a Pd-1 drug in clinical trial not yet approved by Novartis Pharmaceuticals. There is a trial combining Spartalizumab + two targeted therapy drugs, so a triplet trial. There might me some data on how well it is working in that situation, the trial is called Combi-i, here is a link to what I have come across. https://clinicaltrials.gov/ct2/show/study/NCT02967692?show_locs=Y#locn https://ascopubs.org/doi/abs/10.1200/JCO.2016.34.15_suppl.3060
  - May 9, 2019 at 3:07 pm
    
    Quote
    ed williams
    Participant
    
    Here are two more links, one to Novartis and second to article about Spartalizumab. https://www.onclive.com/publications/oncology-live/2018/vol-19-no-22/triplet-therapy-with-novel-pd1-inhibitor-holds-promise-in-melanoma https://www.novartis.com/our-focus/cancer
  - May 9, 2019 at 5:49 pm
    
    Quote
    Linda5
    Participant
    
    Thanks Ed! That’s helpful!

Viewing 0 reply threads

You must be logged in to reply to this topic.

The MRF Patient Forum is the oldest and largest online community of people affected by melanoma. It is designed to provide peer support and information to caregivers, patients, family and friends. There is no better place to discuss different parts of your journey with this cancer and find the friends and support resources to make that journey more bearable.

The information on the forum is open and accessible to everyone. To add a new topic or to post a reply, you must be a registered user. Please note that you will be able to post both topics and replies anonymously even though you are logged in. All posts must abide by MRF posting policies.

Spartalizumab /3 Arm Clinical Trial

About the MRF Patient Forum

Popular Topics

Spartalizumab /3 Arm Clinical Trial

About the MRF Patient Forum

Popular Topics

Topic Tags